Pfizer Opens a Global Research Centre in Chennai
Pfizer Inc. opened a global research centre in Chennai to develop and support drugs for the drugmaker’s manufacturing centres worldwide. The facility is Pfizer’s first such centre in Asia, located at the Indian Institute of Technology (IIT) Madras Research Park, and will employ more than 250 scientists and technicians from different specialities.
The Chennai centre will develop active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) such as complex/value-added formulations, controlled-release dosage forms, device-combination products, lyophilized injections, powder-fill products, and ready-to-use formulations, Pfizer says.
The 61,000 sq. ft centre, built at $20 million, will be part of a network of 12 Pfizer global centres.
S. Sridhar, country manager, Pfizer India says, “we are confident that Pfizer’s drug development centre in the IIT Madras Research Park will allow for synergistic co-development of cutting-edge API and FDF processes under the same roof. The world-class scientific, technology and innovation-driven Research Park campus provides an ideal setting for our work.”
“The centre will initially focus on generic products and, later, on oncology, immunology, and internal medicine,” adds Sridhar.
there is a growing need for pharma firms to provide innovative solutions that can address the new challenges that healthcare providers and patients are facing
S. Aparna, secretary, department of pharmaceuticals says, “there is a growing need for pharma firms to provide innovative solutions that can address the new challenges that healthcare providers and patients are facing. This new centre by Pfizer is a step in that direction. Such efforts to strengthen and expand global work through this centre will allow for knowledge sharing that we hope will improve patient outcomes in the years to come.”